ClinicalTrials.gg
CompletedNCT01560637Updated Jun 2, 2022Results posted

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

A Phase 3 interventional study of UT-15C (treprostinil diolamine) in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 153 sites in 23 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-02.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
471
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
3rd of 44
471 · median 32
Started
2013
with 1 other
Phase 3
14 of 44
1 open now
Registered
21st of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 3rd largest by enrollment, is one of 2 that started in 2013, is one of 14 in phase 3, and was the 21st registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study. The purpose of this study is to assess the long-term safety of UT-15C and to assess the effects of long-term treatment with UT-15C on exercise capacity.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • PAH
  • PH
  • FREEDOM
  • 6 minute walk test
  • treprostinil
  • open label
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participated in United Therapeutics Study TDE-PH-310
  • All women of (WOCBP) must have practiced true abstinence from intercourse when it was in line with their preferred and usual lifestyle or used 2 different forms of highly effective for the duration of the study and for at least 30 days after discontinuing study medication.
  • Males who participated in the study must have used a condom during the length of the study and for at least 48 hours after their last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  • The subject was pregnant or lactating.
  • The subject had received infused or inhaled prostacyclin therapy for 29 days or more.
  • The subject was prematurely discontinued from TDE-PH-310 for reasons other than a clinical worsening event.
  • The subject developed a concurrent illness or condition during the conduct of TDE-PH-310 which, in the opinion of the Investigator, would represent a risk to their overall health if they enrolled in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
471 participants (actual)

Study arms

  • Experimental
    UT-15C

    Open label access

    Drug: UT-15C (treprostinil diolamine)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events

    All subjects who received oral treprostinil in TDE-PH-311 were included in the Safety population. All AEs were captured from the time the ICF was signed. All AEs were followed until resolution (or return to normal or baseline values), until they were judged by the Investigator to no longer be clinically significant, or for up to 30 days if the AE extended beyond the final visit. All SAEs were followed until resolution, death, or the subject was lost to follow-up, even if they were ongoing more than 30 days after completion of the final visit. The overall summary of AEs includes the number of subjects with any AE, the number of subjects with any study drug-related AEs, the number of subjects with AEs leading to study drug withdrawal, the number of subjects with any serious AEs, the number of subjects with any severe AEs, and the number of subjects with any study drug-related severe/serious AEs. AEs were coded using the Medical Dictionary for Regulatory Activities.

    Time frame: Participants will be followed every 12 weeks, at minimum, until they discontinue the study or the study is discontinued by the sponsor or for a period up to 2.5 years

Secondary outcomes

  1. Change in 6-Minute Walk Distance From Baseline

    A summary of change from Baseline in 6MWD at Week 48 for the Safety Population is provided. The Safety Population is all subjects who received oral treprostinil in TDE-PH-311.

    Time frame: Baseline to Week 48

  2. Change in Borg Dyspnea Score From Baseline to Week 48

    Change in Borg Dyspnea Score from at Week 48 is provided for the Safety Population (all subjects who received oral treprostinil in TDE-PH-311). The Borg Dyspnea Scale is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and was administered during six-minute walk testing (6MWT), one of the most common and frequently used measures to assess disease severity in PAH. The numbers on the scale are as follows: 0 (no shortness of breath \[SOB\]), 0.5 (very very slight SOB), 1 (very slight SOB), 3 (moderate SOB), 4 (somewhat severe SOB), 5 (severe SOB), 7 (very severe SOB), 9 (very very severe SOB), 10 (maximal SOB).

    Time frame: Baseline to Week 48

  3. Change From Baseline to Week 48 in WHO Functional Class

    Change from Baseline at Week 48 in WHO FC in the Safety Population (all subjects who received oral treprostinil in TDE-PH-311). The World Health Organization functional classification (WHO-FC) is a clinician-rated assessment used widely to assess PAH severity and functioning. Class I (least severe): Patients are without limitation of physical activity. Class II: Patients are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Marked limitation of physical activity. They are comfortable at rest. Class IV (most severe): Inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure.

    Time frame: Baseline to Week 48

  4. Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 48

    Change in N-terminal pro-brain natriuretic peptide from Baseline at Week 48 for the Safety Population (any subject who received oral treprostinil in TDE-PH-311)

    Time frame: Baseline to Week 48

07

Results

Posted Jun 2, 2022

Participant flow

Participant flow — Overall Study
MilestoneUT-15C
Started470
Completed272
Not completed198
Withdrew: Adverse event63
Withdrew: Death69
Withdrew: Lost to follow-up8
Withdrew: Protocol violation8
Withdrew: Withdrawal by subject24
Withdrew: Progressive disease20
Withdrew: Other reason not specified6

Outcome measures

PrimaryNumber of Adverse Events

All subjects who received oral treprostinil in TDE-PH-311 were included in the Safety population. All AEs were captured from the time the ICF was signed. All AEs were followed until resolution (or return to normal or baseline values), until they were judged by the Investigator to no longer be clinically significant, or for up to 30 days if the AE extended beyond the final visit. All SAEs were followed until resolution, death, or the subject was lost to follow-up, even if they were ongoing more than 30 days after completion of the final visit. The overall summary of AEs includes the number of subjects with any AE, the number of subjects with any study drug-related AEs, the number of subjects with AEs leading to study drug withdrawal, the number of subjects with any serious AEs, the number of subjects with any severe AEs, and the number of subjects with any study drug-related severe/serious AEs. AEs were coded using the Medical Dictionary for Regulatory Activities.

Time frame:
Participants will be followed every 12 weeks, at minimum, until they discontinue the study or the study is discontinued by the sponsor or for a period up to 2.5 years
Reported as:
Number · events
Number of Adverse Events
eventsUT-15C
Adverse Event450
Study Drug Related AE362
AE Leading to Study Drug Withdrawal126
Serious AE206
Severe AE182
Study Drug Related Severe AE67
Study Drug Related Serious AE37
SecondaryChange in 6-Minute Walk Distance From Baseline

A summary of change from Baseline in 6MWD at Week 48 for the Safety Population is provided. The Safety Population is all subjects who received oral treprostinil in TDE-PH-311.

Time frame:
Baseline to Week 48
Reported as:
Mean · meters
Change in 6-Minute Walk Distance From Baseline
metersUT-15C
Change in 6-Minute Walk Distance From Baseline20.1 ± 79.6
SecondaryChange in Borg Dyspnea Score From Baseline to Week 48

Change in Borg Dyspnea Score from at Week 48 is provided for the Safety Population (all subjects who received oral treprostinil in TDE-PH-311). The Borg Dyspnea Scale is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and was administered during six-minute walk testing (6MWT), one of the most common and frequently used measures to assess disease severity in PAH. The numbers on the scale are as follows: 0 (no shortness of breath \[SOB\]), 0.5 (very very slight SOB), 1 (very slight SOB), 3 (moderate SOB), 4 (somewhat severe SOB), 5 (severe SOB), 7 (very severe SOB), 9 (very very severe SOB), 10 (maximal SOB).

Time frame:
Baseline to Week 48
Reported as:
Mean · score on a scale
Change in Borg Dyspnea Score From Baseline to Week 48
score on a scaleUT-15C
Change in Borg Dyspnea Score From Baseline to Week 48-0.49 ± 1.92
SecondaryChange From Baseline to Week 48 in WHO Functional Class

Change from Baseline at Week 48 in WHO FC in the Safety Population (all subjects who received oral treprostinil in TDE-PH-311). The World Health Organization functional classification (WHO-FC) is a clinician-rated assessment used widely to assess PAH severity and functioning. Class I (least severe): Patients are without limitation of physical activity. Class II: Patients are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Marked limitation of physical activity. They are comfortable at rest. Class IV (most severe): Inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure.

Time frame:
Baseline to Week 48
Reported as:
Mean · score on a scale
Change From Baseline to Week 48 in WHO Functional Class
score on a scaleUT-15C
Change From Baseline to Week 48 in WHO Functional Class-0.2 ± 0.6
SecondaryChange in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 48

Change in N-terminal pro-brain natriuretic peptide from Baseline at Week 48 for the Safety Population (any subject who received oral treprostinil in TDE-PH-311)

Time frame:
Baseline to Week 48
Reported as:
Mean · pg/mL
Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 48
pg/mLUT-15C
Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 48-179.23 ± 1968.99

Adverse events

Collected over AEs were recorded for each subject throughout the course of the study from Baseline to 30 days following the final study visit (up to 356 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UT-15C74/470 (15.7%)206/470 (43.8%)467/470 (99.4%)
Most frequent serious events
Showing 10 of 206
Most frequent serious events
EventUT-15C
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders57/470
PneumoniaInfections and infestations32/470
Right ventricular failureCardiac disorders22/470
Cardiac failureCardiac disorders19/470
Septic shockInfections and infestations9/470
Respiratory failureRespiratory, thoracic and mediastinal disorders8/470
Acute kidney injuryRenal and urinary disorders7/470
DyspnoeaRespiratory, thoracic and mediastinal disorders7/470
DiarrhoeaGastrointestinal disorders6/470
GastroenteritisInfections and infestations6/470
Most frequent other events
Showing 10 of 798
Most frequent other events
EventUT-15C
HeadacheNervous system disorders328/470
DiarrhoeaGastrointestinal disorders311/470
FlushingVascular disorders201/470
NauseaGastrointestinal disorders188/470
VomitingGastrointestinal disorders147/470
DizzinessNervous system disorders120/470
Upper respiratory tract infectionInfections and infestations116/470
DyspnoeaRespiratory, thoracic and mediastinal disorders113/470
Pain in jawMusculoskeletal and connective tissue disorders103/470
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders103/470

Baseline characteristics

All 470 subjects who received oral treprostinil during this study are included in the Baseline Analysis Population.

Age, Categorical
Age, Categorical(Participants)UT-15C
<=18 years0
Between 18 and 65 years398
>=65 years72
Age, Continuous
Age, Continuous(years)UT-15C
Mean47.2 ± 15.1
Sex: Female, Male
Sex: Female, Male(Participants)UT-15C
Female374
Male96
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)UT-15C
Hispanic or Latino135
Not Hispanic or Latino334
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)UT-15C
American Indian or Alaska Native0
Asian213
Native Hawaiian or Other Pacific Islander0
Black or African American10
White245
More than one race0
Unknown or Not Reported2
Etiology of Pulmonary Arterial Hypertension (PAH)
Etiology of Pulmonary Arterial Hypertension (PAH)(Participants)UT-15C
Idiopathic of Heritable PAH299
Collagen Vascular Disease114
HIV Infection8
Congenital Heart Defect38
Other11
Background PAH Therapy at Randomization in Parent Study
Background PAH Therapy at Randomization in Parent Study(Participants)UT-15C
Phosphodiesterase Type 5 Inhibitor (PDE5-I) Alone/Soluble Guanylate Cyclase (sGC) Stimulator Alone348
Endothelin Receptor Antagonist (ERA) alone122
Time since Diagnosis
Time since Diagnosis(years)UT-15C
Mean3.16 ± 2.69

2 further baseline measures are reported on the registry.

08

Study locations

153 sites
  • Arizona Pulmonary Specialists, Ltd.
    Phoenix, Arizona 85012, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • University of California, San Francisco-Fresno
    Fresno, California 93701, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90211, United States
  • University of California-Davis Medical Group, Advanced Lung Disease/Transplant Program
    Sacramento, California 95817, United States
  • David Geffen School of Medicine
    Torrance, California 90502, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • University of Florida College of Medicine Jacksonville- Division of Pulmonary & Critical Medicine
    Jacksonville, Florida 32209, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Piedmont - Georgia Lung Associates
    Austell, Georgia 30106, United States
  • HeartCare Midwest
    Peoria, Illinois 61614, United States
  • Indiana University Hospital
    Carmel, Indiana 46032, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 55242, United States
  • Kentuckiana Pulmonary Associates
    Louisville, Kentucky 40202, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Beaumont Health
    Troy, Michigan 48085, United States
  • Nebraska Medical Center
    Omaha, Nebraska 68198-5990, United States
  • Newark Beth Israel Medical Center
    Newark, New Jersey 07112, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Asheville Cardiology Associates
    Asheville, North Carolina 28803, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • University Hospital
    Cleveland, Ohio 44106, United States
  • Ohio State University
    Columbus, Ohio 43321, United States
  • Oregon Health and Science University
    Portland, Oregon 97201-3098, United States
  • Legacy Research Institute
    Portland, Oregon 97210, United States
  • Perelman Center for Advanced Medicine, University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center - Presbyterian Cardiovascular Institute
    Pittsburgh, Pennsylvania 15213, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Sentara Cardiovascular Research Institute
    Norfolk, Virginia 23507, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Aurora Saint Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
  • Sanatorio San José
    Caba, Buenos Aires C1425DUH, Argentina
  • Hospital Italiano de Buenos Aires
    Ciudad Autónoma de Buenos Aires, Distrito Federal C1181ACH, Argentina
  • Hospital Italiano Garibaldi
    Rosario, Santa Fe S2001OAD, Argentina
  • Sanatorio de la Trinidad Mitre
    Buenos Aires, Argentina
  • Hospital Dr. José María Cullen
    Santa Fe, S3000EOY, Argentina
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2751, Australia
  • Saint Vincents Hospital
    Sydney, New South Wales 2010, Australia
  • Macquarie University
    Sydney, New South Wales 2109, Australia
  • Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Krankenhaus Elisabethinen Linz
    Linz, Upper Austria 4020, Austria
  • Medizinische Universität Wien
    Wien, 1090, Austria
  • Hospital das Clinicas da Universidade Federal de Goias
    Goiania, Goias 74605-050, Brazil
  • Hospital das Clínicas da Universidade Federal de Minas Gerais
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Hospital Madre Teresa
    Belo Horizonte, Minas Gerais 30380-090, Brazil
  • Complexo Hospitalar Santa Casa de Porto Alegre
    Porto Alegre, RIO Grande DO SUL 90020-090, Brazil
  • Hospital das Clínicas da Faculdade de Medicina de Botucatu- UNESP
    Botucatu, SAO Paulo 18618-970, Brazil
  • Hospital da Clínicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, SAO Paulo 05403-000, Brazil
  • Escola Paulista de Medicina, Universidade Federal de São Paulo
    São Paulo, SAO Paulo, Brazil
  • Hospital Alemão Oswaldo Cruz
    São Paulo, 01323-020, Brazil
  • Respiratory Research Foundation
    Calgary, Alberta T1Y 6J4, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Vancouver Coastal Health
    Vancouver, British Columbia V5Z 1M9, Canada
  • Lawson Health Research Institute
    London, Ontario N6A 5A5, Canada
  • Centro de Investigaciones TASOL
    Santiago, Region Metropolitana 7500710, Chile
  • Clínica Tabancura
    Vitacura, Santiago 7650018, Chile
  • Beijing Chao-Yang Hospital
    Beijing, Beijing 100020, China
  • Guangdong General Hospital
    Guangzhou, Guangdong 510080, China
  • Wuhan Asia Heart Hospital
    Wuhan, Hubei 430022, China
  • Xiangya Hospital
    Changsha, Hunan 410008, China
  • The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210029, China
  • The Second Affiliated Hospital of Nanchang Medical University
    Nanchang, Jiangxi 330006, China
  • Zhongshan Hospital Fudan University
    Shanghai, Shanghai 200032, China
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200120, China
  • West China Hospital
    Chengdu, Sichuan 610047, China
  • Peking Union Medical College Hospital
    Beijing, 100005, China
  • Beijing Shijitan Hospital
    Beijing, 100038, China
  • Chinese PLA General Hospital
    Beijing, 100853, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, 26603, China
  • Renji Hospital of Shanghai Jiaotong University
    Shanghai, 200001, China
  • Shanghai Pulmonary Hospital of Tongji University
    Shanghai, 200433, China
  • Shenyang General Hospital of Shenyang Military Command
    Shenyang, 110015, China
  • Aarhus Universitetshospital, Skejby
    Aarhus, 8200, Denmark
  • Rigshospitalet-Copenhagen University Hospital
    Copenhagen, 2100, Denmark
  • Hopital Haut-Leveque, CHU Bordeaux
    Pessac, Aquitaine 33064, France
  • Hopital Jean Minjoz Centre Hospitalier Universitaire Besancon
    Besancon, Franche-comte 25030, France
  • CHU de Montpellier
    Montpellier cedex 5, Languedoc-roussillon 34295, France
  • Hopital Brabois
    Vandoeuvre-Les-Nancy, Limousin, Lorraine 54500, France
  • Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez
    Lille, NORD Pas-de-calais 59037, France
  • Centre Hospitalier Universitaire Hopital Nord
    Marseille, Provence Alpes COTE D'azur 13015, France
  • Thoraxklinik am Universitätsklinikum Heidelberg
    Heidelberg, Baden-wuerttemberg 69126, Germany
  • Ludwig-Maximilians-Universitat Munchen
    Munchen, Bayern 81377, Germany
  • Universitätsklinikum Regensburg
    Regensburg, Bayern 93053, Germany
  • Missionsarztliche Klinik Wurzburg gGmbH
    Wurzburg, Bayern 97074, Germany
  • Universitätsmedizin Greifswald
    Greifswald, Mecklenburg-vorpommern 17475, Germany
  • Bergmannsheil Berufsgenossenschaftliche Universitätsklinik GmbH
    Bochum, Nordrhein-westfalen 44789, Germany
  • Herzzentrum Duisburg
    Duisburg, Nordrhein-westfalen 47137, Germany
  • Universitätsklinikum Köln
    Köln, Nordrhein-westfalen 50937, Germany
  • Universitätsmedizin der Johannes Gutenberg Universität
    Mainz, Rheinland-pfalz 55131, Germany

Showing the first 100 of 153 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Aug 2021, 95 months.

Results were first posted in Jun 2022, 9 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 95 months is above that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2012
First posted
Mar 22, 2012
StartActual
Sep 11, 2013
Primary completionActual
Aug 12, 2021
CompletionActual
Aug 12, 2021
Results first posted
Jun 2, 2022
Last update
Jun 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01560637
Responsible party
Sponsor
First posted
Mar 22, 2012
Start date
Sep 11, 2013
Primary completion
Aug 12, 2021
Completion
Aug 12, 2021
Results posted
Jun 2, 2022
Last update
Jun 2, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion